10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics: Still Waiting For Entry

06:55am, Saturday, 20'th Jan 2024
10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform

10x Genomics: Unveiling The Investment Potential

01:02am, Saturday, 04'th Nov 2023
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - C
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall
10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance in both single-cell and spatial biology portfolios.
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compar
10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.57 per share a year ago.
Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation.

10x Genomics: Growth Outweighing The Risks

10:55am, Saturday, 24'th Jun 2023
10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing s

Red-Hot Quality Opportunities in Genomics

02:21pm, Thursday, 22'nd Jun 2023
The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive m
On May 23, 2023, Serge Saxonov, CEO of 10x Genomics Inc ( TXG , Financial), sold 2,602 shares of the company's stock. This insider sell comes amidst a year of insider transactions that have seen Saxon
It could be an inflection year for 10x Genomics, one analyst says. TXG stock bounded off a low in October and is now on a seven-month sprint.
Biology is the study of life. And synthetic biology is the creation of new life for new purposes.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE